Global and China Uterine Fibroid Treatment Market Size, Status and Forecast 2020-2026

Published On: Jul 2020

Format: PDF

Publisher: QY Research

Pages: 95

Report ID: 199239

Global Uterine Fibroid Treatment Scope and Market Size
Uterine Fibroid Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Uterine Fibroid Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Market segment by Type, the product can be split into
Endometrial Ablation
MRI Guided Procedures
Hysterectomy
Myomectomy
Uterine Artery Embolization
Radiofrequency Ablation
Others

Market segment by Application, split into
Hospital
Clinic
Other

Based on regional and country-level analysis, the Uterine Fibroid Treatment market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa

In the competitive analysis section of the report, leading as well as prominent players of the global Uterine Fibroid Treatment market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The key players covered in this study
Blue Endo
Boston Scientific Corporation
CooperSurgical, Inc.
KARL STORZ SE & Co. KG
Myovant Sciences (Sumitovant Biopharma Ltd.)
Halt Medical, Inc.
LiNA Medical USA
Merit Medical Systems
Olympus Corporation
Richard Wolf GmbH

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Uterine Fibroid Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 Endometrial Ablation
1.2.3 MRI Guided Procedures
1.2.4 Hysterectomy
1.2.5 Myomectomy
1.2.6 Uterine Artery Embolization
1.2.7 Radiofrequency Ablation
1.2.8 Others
1.3 Market by Application
1.3.1 Global Uterine Fibroid Treatment Market Share by Application: 2020 VS 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Uterine Fibroid Treatment Market Perspective (2015-2026)
2.2 Global Uterine Fibroid Treatment Growth Trends by Regions
2.2.1 Uterine Fibroid Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Uterine Fibroid Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Uterine Fibroid Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Uterine Fibroid Treatment Players by Market Size
3.1.1 Global Top Uterine Fibroid Treatment Players by Revenue (2015-2020)
3.1.2 Global Uterine Fibroid Treatment Revenue Market Share by Players (2015-2020)
3.2 Global Uterine Fibroid Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Uterine Fibroid Treatment Revenue
3.4 Global Uterine Fibroid Treatment Market Concentration Ratio
3.4.1 Global Uterine Fibroid Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Uterine Fibroid Treatment Revenue in 2019
3.5 Key Players Uterine Fibroid Treatment Area Served
3.6 Key Players Uterine Fibroid Treatment Product Solution and Service
3.7 Date of Enter into Uterine Fibroid Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Uterine Fibroid Treatment Breakdown Data by Type (2015-2026)
4.1 Global Uterine Fibroid Treatment Historic Market Size by Type (2015-2020)
4.2 Global Uterine Fibroid Treatment Forecasted Market Size by Type (2021-2026)

5 Uterine Fibroid Treatment Breakdown Data by Application (2015-2026)
5.1 Global Uterine Fibroid Treatment Historic Market Size by Application (2015-2020)
5.2 Global Uterine Fibroid Treatment Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Uterine Fibroid Treatment Market Size (2015-2026)
6.2 North America Uterine Fibroid Treatment Market Size by Type (2015-2020)
6.3 North America Uterine Fibroid Treatment Market Size by Application (2015-2020)
6.4 North America Uterine Fibroid Treatment Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada

7 Europe
7.1 Europe Uterine Fibroid Treatment Market Size (2015-2026)
7.2 Europe Uterine Fibroid Treatment Market Size by Type (2015-2020)
7.3 Europe Uterine Fibroid Treatment Market Size by Application (2015-2020)
7.4 Europe Uterine Fibroid Treatment Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe

8 China
8.1 China Uterine Fibroid Treatment Market Size (2015-2026)
8.2 China Uterine Fibroid Treatment Market Size by Type (2015-2020)
8.3 China Uterine Fibroid Treatment Market Size by Application (2015-2020)
8.4 China Uterine Fibroid Treatment Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific

9 Japan
9.1 Japan Uterine Fibroid Treatment Market Size (2015-2026)
9.2 Japan Uterine Fibroid Treatment Market Size by Type (2015-2020)
9.3 Japan Uterine Fibroid Treatment Market Size by Application (2015-2020)
9.4 Japan Uterine Fibroid Treatment Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil

10 Southeast Asia
10.1 Southeast Asia Uterine Fibroid Treatment Market Size (2015-2026)
10.2 Southeast Asia Uterine Fibroid Treatment Market Size by Type (2015-2020)
10.3 Southeast Asia Uterine Fibroid Treatment Market Size by Application (2015-2020)
10.4 Southeast Asia Uterine Fibroid Treatment Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa

11Key Players Profiles
11.1 Blue Endo
11.1.1 Blue Endo Company Details
11.1.2 Blue Endo Business Overview
11.1.3 Blue Endo Uterine Fibroid Treatment Introduction
11.1.4 Blue Endo Revenue in Uterine Fibroid Treatment Business (2015-2020))
11.1.5 Blue Endo Recent Development
11.2 Boston Scientific Corporation
11.2.1 Boston Scientific Corporation Company Details
11.2.2 Boston Scientific Corporation Business Overview
11.2.3 Boston Scientific Corporation Uterine Fibroid Treatment Introduction
11.2.4 Boston Scientific Corporation Revenue in Uterine Fibroid Treatment Business (2015-2020)
11.2.5 Boston Scientific Corporation Recent Development
11.3 CooperSurgical, Inc.
11.3.1 CooperSurgical, Inc. Company Details
11.3.2 CooperSurgical, Inc. Business Overview
11.3.3 CooperSurgical, Inc. Uterine Fibroid Treatment Introduction
11.3.4 CooperSurgical, Inc. Revenue in Uterine Fibroid Treatment Business (2015-2020)
11.3.5 CooperSurgical, Inc. Recent Development
11.4 KARL STORZ SE & Co. KG
11.4.1 KARL STORZ SE & Co. KG Company Details
11.4.2 KARL STORZ SE & Co. KG Business Overview
11.4.3 KARL STORZ SE & Co. KG Uterine Fibroid Treatment Introduction
11.4.4 KARL STORZ SE & Co. KG Revenue in Uterine Fibroid Treatment Business (2015-2020)
11.4.5 KARL STORZ SE & Co. KG Recent Development
11.5 Myovant Sciences (Sumitovant Biopharma Ltd.)
11.5.1 Myovant Sciences (Sumitovant Biopharma Ltd.) Company Details
11.5.2 Myovant Sciences (Sumitovant Biopharma Ltd.) Business Overview
11.5.3 Myovant Sciences (Sumitovant Biopharma Ltd.) Uterine Fibroid Treatment Introduction
11.5.4 Myovant Sciences (Sumitovant Biopharma Ltd.) Revenue in Uterine Fibroid Treatment Business (2015-2020)
11.5.5 Myovant Sciences (Sumitovant Biopharma Ltd.) Recent Development
11.6 Halt Medical, Inc.
11.6.1 Halt Medical, Inc. Company Details
11.6.2 Halt Medical, Inc. Business Overview
11.6.3 Halt Medical, Inc. Uterine Fibroid Treatment Introduction
11.6.4 Halt Medical, Inc. Revenue in Uterine Fibroid Treatment Business (2015-2020)
11.6.5 Halt Medical, Inc. Recent Development
11.7 LiNA Medical USA
11.7.1 LiNA Medical USA Company Details
11.7.2 LiNA Medical USA Business Overview
11.7.3 LiNA Medical USA Uterine Fibroid Treatment Introduction
11.7.4 LiNA Medical USA Revenue in Uterine Fibroid Treatment Business (2015-2020)
11.7.5 LiNA Medical USA Recent Development
11.8 Merit Medical Systems
11.8.1 Merit Medical Systems Company Details
11.8.2 Merit Medical Systems Business Overview
11.8.3 Merit Medical Systems Uterine Fibroid Treatment Introduction
11.8.4 Merit Medical Systems Revenue in Uterine Fibroid Treatment Business (2015-2020)
11.8.5 Merit Medical Systems Recent Development
11.9 Olympus Corporation
11.9.1 Olympus Corporation Company Details
11.9.2 Olympus Corporation Business Overview
11.9.3 Olympus Corporation Uterine Fibroid Treatment Introduction
11.9.4 Olympus Corporation Revenue in Uterine Fibroid Treatment Business (2015-2020)
11.9.5 Olympus Corporation Recent Development
11.10 Richard Wolf GmbH
11.10.1 Richard Wolf GmbH Company Details
11.10.2 Richard Wolf GmbH Business Overview
11.10.3 Richard Wolf GmbH Uterine Fibroid Treatment Introduction
11.10.4 Richard Wolf GmbH Revenue in Uterine Fibroid Treatment Business (2015-2020)
11.10.5 Richard Wolf GmbH Recent Development

12Analyst's Viewpoints/Conclusions

13Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details